HbA1c AND THE RISK OF DIABETIC RETINOPATHY PROGRESSION: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6286Keywords:
Glycated Hemoglobin (HbA1c); Diabetic Retinopathy; Diabetes Mellitus; Glycemic Control; Microvascular Complications; Retinal DiseaseAbstract
Background: Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes mellitus and remains a leading cause of preventable vision loss worldwide. Glycated hemoglobin (HbA1c), reflecting long-term glycemic control, is widely recognized as an important biomarker for assessing the risk of diabetic complications.
Objective: This narrative review aimed to summarize current evidence regarding the relationship between HbA1c levels and the development and progression of diabetic retinopathy, with particular emphasis on its clinical significance in risk assessment and disease prevention.
Methods: A review of landmark randomized controlled trials, epidemiological studies, systematic reviews, meta-analyses, and current clinical guidelines was conducted. Evidence from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), ACCORD, ADVANCE, and recent reviews was synthesized to evaluate the role of HbA1c in diabetic retinopathy.
Results: The available evidence consistently demonstrates that elevated HbA1c levels are strongly associated with an increased risk of developing and progressing diabetic retinopathy in both type 1 and type 2 diabetes mellitus. Sustained improvement in glycemic control significantly reduces the risk of retinal complications, although no universally accepted HbA1c threshold predicting disease onset has been established. HbA1c should therefore be interpreted as a continuous biomarker of retinal risk alongside other clinical risk factors.
Conclusions: HbA1c remains one of the most valuable modifiable predictors of diabetic retinopathy and an essential component of individualized diabetes management. Optimizing long-term glycemic control, combined with regular ophthalmologic assessment and comprehensive risk factor management, remains the cornerstone of preventing diabetic retinopathy progression and preserving visual function.
References
Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329(14), 977–986. https://doi.org/10.1056/NEJM199309303291401
UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837–853. https://doi.org/10.1016/S0140-6736(98)07019-6
Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321(7258), 405–412. https://doi.org/10.1136/bmj.321.7258.405
Klein, R., Klein, B. E. K., & Moss, S. E. (1994). The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of Internal Medicine, 154(16), 1817–1829.
Klein, R., Klein, B. E. K., & Moss, S. E. (1988). Glycemic control and diabetic retinopathy. JAMA, 260(19), 2864–2871.
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S. J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., . . . Wong, T. Y. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35(3), 556–564. https://doi.org/10.2337/dc11-1909
Ding, J., & Wong, T. Y. (2012). Current epidemiology of diabetic retinopathy. Current Diabetes Reports, 12(4), 346–356. https://doi.org/10.1007/s11892-012-0283-6
Cheung, N., Mitchell, P., & Wong, T. Y. (2010). Diabetic retinopathy. The Lancet, 376(9735), 124–136. https://doi.org/10.1016/S0140-6736(09)62124-3
Al Ghamdi, A. H. (2020). Clinical predictors of diabetic retinopathy. Current Diabetes Reviews, 16(6), 575–585. https://doi.org/10.2174/1573399815666190116143740
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 32(1), 193–203. https://doi.org/10.2337/dc08-9025
Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615–1625. https://doi.org/10.2337/diabetes.54.6.1615
Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137–188. https://doi.org/10.1152/physrev.00045.2011
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H. P., Simó, R., Lois, N., & Medina, R. J. (2016). The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research, 51, 156–186. https://doi.org/10.1016/j.preteyeres.2015.08.001
Teo, Z. L., Tham, Y. C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y., Lu, Y., Wong, I. Y. H., Ting, D. S. W., Tan, G. S. W., Jonas, J. B., Sabanayagam, C., & Wong, T. Y. (2021). Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis. Ophthalmology, 128(11), 1580–1591. https://doi.org/10.1016/j.ophtha.2021.04.027
Jin, P., Peng, Q., Zhang, X., Wang, X., Sun, X., & Xu, J. (2015). HbA1c levels and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: A meta-analysis. PLOS ONE, 10(8), e0134666. https://doi.org/10.1371/journal.pone.0134666
ACCORD Study Group, & ACCORD Eye Study Group. (2010). Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine, 363(3), 233–244. https://doi.org/10.1056/NEJMoa1001288
ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560–2572. https://doi.org/10.1056/NEJMoa0802987
Sabanayagam, C., & Wong, T. Y. (2014). Diabetic retinopathy: Global prevalence, major risk factors, screening practices, and public health challenges. JAMA Ophthalmology, 132(5), 607–618. https://doi.org/10.1001/jamaophthalmol.2014.998
American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Supplement 1), S1–S350. https://doi.org/10.2337/dc24-SINT
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Julia Łukasik, Karolina Bałdys, Klaudia Jeziorowska, Maria Całusińska-Skowron, Aleksandra Regina Żmuda, Aleksandra Karolina Schmidt, Kornel Adrian Jarosz, Anna Kudłacik, Magdalena Franków, Oktawian Kaczmarek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
